Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$34.01 USD
-1.15 (-3.27%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $33.98 -0.03 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/11/2025
Time: -- |
9/2025 | $-0.10 | 0.00% |
Earnings Summary
For their last quarter, Legend Biotech (LEGN) reported earnings of -$0.34 per share, missing the Zacks Consensus Estimate of -$0.22 per share. This reflects a negative earnings surprise of 54.55%. Look out for LEGN's next earnings release expected on November 11, 2025. For the next earning release, we expect the company to report earnings of -$0.10 per share, reflecting a year-over-year increase of 70.59%.
Earnings History
Price & Consensus
Zacks News for LEGN
Key Inflation Data in Focus
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pre-Markets in Green, Inflation Data, Retail Sales, Q2 Earnings This Week
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
What Makes Legend Biotech (LEGN) a New Buy Stock
LEGN FAQs
Based on past history, Zacks believes Legend Biotech Corporation Sponsored ADR (LEGN) will report their next quarter earnings on November 11, 2025. For the next earning release, we expect the company to report earnings of -0.10 per share, reflecting a year-over-year increase of 70.59.
Based on past history, Zacks believes Legend Biotech Corporation Sponsored ADR (LEGN) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 11, 2025.
The Zacks Consensus Estimate for Legend Biotech Corporation Sponsored ADR (LEGN) for the quarter ending September 2025 is $-0.10 a share. We expect Legend Biotech Corporation Sponsored ADR (LEGN) to report earnings in line with the consensus estimate of $-0.10 per share
In the earnings report for the quarter ending in June 2024, Legend Biotech Corporation Sponsored ADR (LEGN) announced earnings of $-0.05 per share versus the Zacks Consensus Estimate of $-0.54 per share, representing a surprise of -90.74%.